The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
Tilman Fertitta told CNBC on Monday that he is doing things in a "very conservative way" amid fears of a recession.Marketsread more
Saudi Aramco sent a request for proposal to several banks, people familiar with the matter told CNBC on Monday.Marketsread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
Leaked documents from Google give fresh ammo to conservative lawmakers who have already accused Google and other tech companies of political bias.Technologyread more
J.P. Morgan estimates the average annual tariff cost per household will be $1,000 with the new round of Trump's tariffs.Marketsread more
Stasior left Apple earlier this year. Prior to his time in charge of Siri, he was a top executive at Amazon.Technologyread more
Roche said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.
The Swiss company said it was extending its offer to May 2 from the original deadline of Wednesday, having received support from holders of only 29.4 percent of Spark shares. It needs a majority for its offer to go through.
A spokesman said Roche remained confident the deal would be completed by the end of June.
"All terms and conditions of the offer shall remain unchanged during the extended period," Roche said in a statement on the $114.50 per share offer it announced in February.
Roche also said a review of the acquisition by the U.S. Federal Trade Commission (FTC), the government agency which seeks to prevent anti-competitive practices, was taking more time than anticipated and its plans had had to be refiled.
It did not give any further detail on the refiling but said it had been agreed with the FTC and with Spark.
"The FTC review and clearance is required for the deal to be completed and needs more time," a Roche spokesman said.
"The deal is not in doubt at all and we expect it will be completed according to our guidance in the first half of 2019. There needs to be more than 50 percent of the shares to be tendered, but we believe our offer to be full and fair and it has been recommended by the board of Spark," the spokesman added.
Spark shares closed at $114.01 on Tuesday. Roche shares were down 0.3 percent in early trade.
Gene therapies use specially engineered viruses to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.
Roche offered more than twice the Philadelphia-based company's closing price on Feb. 22 for a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for haemophilia and neurodegenerative disorders such as Huntington's disease.
The offer came as rivals including Novartis also move into gene therapy, where treatments for rare, inherited diseases command some of the highest prices in medicine.
Spark's blindness therapy Luxturna for instance is priced at $850,000 per patient. The treatment had sales of $27 million in 2018.
However Spark faces at least three lawsuits in the United States by shareholders challenging the sale, on grounds that it undervalues Spark's stock and is unfair to shareholders.
Roche on Wednesday declined to comment on the lawsuits.
Roche Chief Executive Severin Schwan is interested in gene therapies to help compensate for patent losses on his $21 billion per year trio of cancer medicines Rituxan, Herceptin and Avastin, which are facing competition from cheaper copies.
Spark, which also has product candidates that have shown promising early results in patients with haemophilia, reduced its net loss to $78.7 million in 2018, while revenue increased to $64.7 million.